Related Experiment Video
Updated: Aug 9, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
Published on: June 4, 2012
Potential applications of RNA interference technology in the treatment of cancer
1Charité Campus Mitte, Institute of Pathology, For-schumannstr. 20/21 D-10117 Berlin, Germany hermann.lage@charite.de
Abstract:
Inhibition of growth and progression of cancer cells is a challenge with major potential impact. RNA interference (RNAi) technology has been rapidly developed as a laboratory tool for the downregulation of the expression of a gene of interest. Moreover, RNAi offers a new potential for gene therapy of particular neoplasms by the specific inhibition of a cancer-associated target. This article will briefly describe the mechanism and application possibilities of RNAi, and illustrate the therapeutic potential in cancer gene therapy. The utilization of RNAi technology as a potential therapeutic tool for the treatment of cancer will be discussed in detail for two specific targets; the Bcr-Abl tyrosine kinase and the multidrug transporter MDR1/P-glycoprotein.
Insights
RNA interference (RNAi) offers a novel approach to cancer gene therapy by downregulating specific cancer-associated genes. This technology shows therapeutic potential for treating neoplasms by targeting key molecules like Bcr-Abl and MDR1.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Cancer cell growth and progression present significant therapeutic challenges.
- RNA interference (RNAi) is a powerful laboratory tool for gene expression downregulation.
- RNAi holds promise for targeted gene therapy in oncology.
Purpose of the Study:
- To describe the mechanism and applications of RNAi technology.
- To illustrate the therapeutic potential of RNAi in cancer gene therapy.
- To discuss RNAi's application for targeting Bcr-Abl tyrosine kinase and MDR1/P-glycoprotein.
Main Methods:
- Review of RNAi mechanisms.
- Analysis of RNAi application possibilities in cancer.
- Detailed discussion of specific cancer targets for RNAi therapy.
Main Results:
- RNAi technology facilitates specific gene silencing.
- RNAi demonstrates potential for targeted cancer gene therapy.
- Bcr-Abl tyrosine kinase and MDR1/P-glycoprotein are viable targets for RNAi.
Conclusions:
- RNAi is a promising strategy for cancer treatment.
- Targeted gene inhibition via RNAi can combat specific neoplasms.
- Further research into RNAi applications in oncology is warranted.
Related Concept Videos
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibitors of Viral Protein Synthesis
Small interfering RNAs (siRNA)
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

